|
|
Vaccine Detail
|
Canvaxin |
| Vaccine Information |
- Vaccine Name: Canvaxin
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007591
- Type: Allogenic whole-cell
- Status: Research
- Antigen: TA90
- Preparation: An irradiated allogeneic whole-cell vaccine composed of cells from three melanoma cell lines (Faries et al., 2009).
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Human Response
- Vaccine Immune Response Type: VO_0003057
- Immune Response: GM-CSF arm showed enhanced antibody responses with an increase in IgM titer against the TA90 antigen and increased TA90 immune complexes. Peripheral blood leukocyte profiles showed increases in eosinophils and basophils with decreased monocytes in the GM-CSF arm (Faries et al., 2009).
|
| References |
Faries et al., 2009: Faries MB, Hsueh EC, Ye X, Hoban M, Morton DL. Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009; 15(22); 7029-7035. [PubMed: 19903777].
|
|
